摘要
                
                    目的研究在食管癌高危人群检测血清中肿瘤相关自身抗体的意义。方法应用间接酶联免疫反应法和肿瘤相关抗原微阵列(包含八个重组的癌抗原蛋白C-myc,p53,cyclinB1,p16,p62,Koc,IMP1,Survivin)检测391例食管癌高发区人群血清中的自身抗体。然后作胃镜检查和活检,对照自身抗体阳性组和阴性组的食管病理变化情况。结果对血清自身抗体阳性者64例和血清自身抗体阴性者67例作胃镜检查和组织活检。血清自身抗体阳性组食管上皮正常率明显低于血清自身抗体阴性组(P<0.01)。随着病变程度的加重,血清自身抗体阳性表达的频率增加。结论联合应用多个肿瘤相关抗原检测血清中的自身抗体对筛查食管癌和高危人群预警有实用意义。
                
                Objective To study the significance of tumor - associated autoantibody measurement in serum from high - risk subjects of esopha- geal cancers. Methods Enzyme - linked immunoassay and tumor - associated antigen mini - array ( consisting of eight full - length recombinant proteins, including C - myc, p53, cyclinB 1, p62, pl 6, Koc, IMP1, survivin) were applied to screen the serum level of the autoantibody in 391 subjects in Lin Zhou City. Gastroscopy and biopsy were done for the subjects with autoantibody positive group and control group. Results Gastroscopy and biopsy were done in 64 cases which at least one autoantibody was positive and 67 cases who were negative in autoantibody. The ratio of normal esophagus with autoantibody positive was significantly lower than that of negative( P 〈 0. 01 ). Autoantibody frequency tended to increase stepwise with the lesion grades increasing( P 〈 0.01 ). Conclusion The multiple tumor - associated antigens mini - array for autoantibody measurement in screening esophageal cancer may contribute a clinically approach to the high - risk subjects and early cancer diagnosis.
    
    
    
    
                出处
                
                    《临床和实验医学杂志》
                        
                        
                    
                        2007年第6期3-5,共3页
                    
                
                    Journal of Clinical and Experimental Medicine
     
            
                基金
                    国家杰出青年科学基金30025016
            
    
                关键词
                    肿瘤相关抗原
                    自身抗体食管癌
                    高危人群
                    筛查
                
                        Tumor - associated antigens 
                         Autoantibody
                         Esophagus cancer
                         High - risk subject Screening